Last reviewed · How we verify
RSV sF 50 mcg
At a glance
| Generic name | RSV sF 50 mcg |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV sF 50 mcg CI brief — competitive landscape report
- RSV sF 50 mcg updates RSS · CI watch RSS
- MedImmune LLC portfolio CI